Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

October 13, 2020

Primary Completion Date

July 14, 2021

Study Completion Date

August 19, 2021

Conditions
Atopic Dermatitis
Interventions
BIOLOGICAL

FB-401

Topical application

BIOLOGICAL

Placebo

Vehicle

Trial Locations (15)

19073

KGL Skin Study Center LLC, Newtown Square

20850

Lawrence J. Green MD LLC, Rockville

27262

Dermatology Consulting Services, PLLC, High Point

30263

MedaPhase, Inc., Newnan

32055

Multi-Specialty Research Associates, Inc., Lake City

40241

DS Research, Louisville

46168

The Indiana Clinical Trials Center, Plainfield

47129

DS Research, Clarksville

55112

Minnesota Clinical Study Center, New Brighton

68516

Midwest Children's Health Research Institute, Lincoln

77401

Bellaire Dermatology Associates, Bellaire

78218

Texas Dermatology and Laser Specialists, San Antonio

92708

First OC Dermatology, Fountain Valley

94538

Center for Dermatology Clinical Research, Inc., Fremont

97030

Cyn3rgy Research, Gresham

Sponsors
All Listed Sponsors
lead

Forte Biosciences, Inc.

INDUSTRY

NCT04504279 - Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis | Biotech Hunter | Biotech Hunter